Cerebral infarction
Conditions
Interventions
Control group: standard therapy Three months
Cilostazol group: cilostazol 200mg/day + standard therapy Three months
Sponsors
Tohoku Acute Progressing Stroke Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Non-cardioembolic cerebral infarction with patient's ages > or = 20 and < 80 y.o. 2) First or recurrent stroke 3) Within 24 hours after the onset 4) Stable general condition
Exclusion criteria
Exclusion criteria: 1) mRS before the onset > or = 2 2) NIHSS score > or = 20 3) Remarkably unstable symptom (measurement of NIHSS difficult) 4) Patients who should be treated with alteplase or other thrombolytic therapies 5) Patients who should be treated with reconstructive surgery (bypass or endovascular treatment) 6) Severe swallowing disturbance 7) Serious systemic complications (carcinoma,liver cirrhosis,renal failure, heart failure, etc.) 8) Contraindications to cilostazol 9) Patients who are considered unsuitable for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Proportion of the patients with mRS score 0 or 1 at 3 months follow-up 2) Incidence of the progressing stroke (worsening of the NIHSS score by 4 points or more) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Incidence of cardiovascular events 2) Proportion of the patients with mRS score of 0 or 1 at 1 month follow-up 3) Proportion of patients with favorable outcome (mRS scores 0,1 or 2) at 1 and 3 months | — |
Countries
Japan
Contacts
Public ContactHiroaki Shimizu
Tohoku university graduate school of medicine Neuroendovascular Therapy
Outcome results
None listed